Shanghai Hile Bio-tech (603718) — Working Capital to Net Assets Ratio
Shanghai Hile Bio-tech (603718) has a Working Capital to Net Assets ratio of 38.5% as of June 2026. Working capital of CN¥373.75 Million (current assets of CN¥600.82 Million minus current liabilities of CN¥227.07 Million) is measured against net assets of CN¥971.57 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See defensive interval ratio of Shanghai Hile Bio-tech to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shanghai Hile Bio-tech Working Capital to Net Assets (2011–2025)
This chart shows how Shanghai Hile Bio-tech's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 38.5%, reflecting working capital of CN¥373.75 Million against net assets of CN¥971.57 Million CNY. For the complete balance sheet picture, see 603718 total assets.
Annual Working Capital to Net Assets for Shanghai Hile Bio-tech (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Hile Bio-tech from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check how resilient are Shanghai Hile Bio-tech's assets to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 54.1% | CN¥484.30 Million | CN¥895.97 Million | CN¥595.84 Million | CN¥111.54 Million | ▲ +19.3 pp |
| 2024 | 34.7% | CN¥591.53 Million | CN¥1.70 Billion | CN¥691.77 Million | CN¥100.25 Million | ▲ +22.3 pp |
| 2023 | 12.4% | CN¥145.51 Million | CN¥1.17 Billion | CN¥562.55 Million | CN¥417.04 Million | ▼ -18.6 pp |
| 2022 | 31.0% | CN¥344.28 Million | CN¥1.11 Billion | CN¥665.03 Million | CN¥320.75 Million | ▲ +0.0 pp |
| 2021 | 30.9% | CN¥305.48 Million | CN¥987.19 Million | CN¥975.44 Million | CN¥669.96 Million | ▲ +20.3 pp |
| 2020 | 10.7% | CN¥102.48 Million | CN¥962.20 Million | CN¥742.49 Million | CN¥640.01 Million | ▼ -6.0 pp |
| 2019 | 16.7% | CN¥165.50 Million | CN¥992.57 Million | CN¥805.84 Million | CN¥640.34 Million | ▲ +4.0 pp |
| 2018 | 12.7% | CN¥130.15 Million | CN¥1.03 Billion | CN¥787.47 Million | CN¥657.31 Million | ▼ -20.9 pp |
| 2017 | 33.6% | CN¥361.21 Million | CN¥1.07 Billion | CN¥818.47 Million | CN¥457.27 Million | ▼ -23.0 pp |
| 2016 | 56.6% | CN¥569.15 Million | CN¥1.01 Billion | CN¥828.52 Million | CN¥259.38 Million | ▼ -14.2 pp |
| 2015 | 70.8% | CN¥682.02 Million | CN¥963.31 Million | CN¥787.99 Million | CN¥105.97 Million | ▲ +16.1 pp |
| 2014 | 54.7% | CN¥305.41 Million | CN¥558.50 Million | CN¥352.53 Million | CN¥47.12 Million | ▼ -3.5 pp |
| 2013 | 58.2% | CN¥291.26 Million | CN¥500.66 Million | CN¥354.41 Million | CN¥63.15 Million | ▲ +5.6 pp |
| 2012 | 52.6% | CN¥246.08 Million | CN¥467.89 Million | CN¥309.88 Million | CN¥63.80 Million | ▲ +11.2 pp |
| 2011 | 41.4% | CN¥167.81 Million | CN¥405.74 Million | CN¥244.96 Million | CN¥77.15 Million | — |